OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.
- FDA grants HDE approval for OncoSil™ in distal cholangiocarcinoma
- First and only Class III device approved for this rare bile duct cancer
- US addressable market estimated at 1,000 patients and A$80 million
- Initial use limited to five centres under post-approval study
- US commercial launch planned for second half of FY27
FDA Approval Marks Major Regulatory Milestone
OncoSil Medical (ASX:OSL) has crossed a significant threshold with the US Food and Drug Administration granting Humanitarian Device Exemption (HDE) approval for its OncoSil™ device to treat distal cholangiocarcinoma (dCCA). This approval is the first of its kind for a Class III device targeting this rare and aggressive bile duct cancer, representing a pivotal step in OncoSil’s US expansion strategy.
The HDE approval allows OncoSil to market its device in the US for unresectable, non-metastatic dCCA patients, a group with extremely limited treatment options and a median survival of just 6.7 months. This regulatory pathway acknowledges the rarity of the disease, affecting fewer than 8,000 individuals annually in the US, and balances safety with probable benefit rather than requiring full effectiveness demonstration.
Addressable Market and Commercial Launch Plans
The US market opportunity for OncoSil’s device is estimated at around 1,000 eligible patients per year, translating to an annual total addressable market of approximately A$80 million based on a US$55,000 selling price per treatment. OncoSil plans to target leading academic cancer centres and specialist hepatobiliary oncology teams, aiming for a commercial launch in the second half of FY27.
Initial use of the device will be restricted to a maximum of five treatment centres as part of an FDA-mandated post-approval study (PAS). This multicentre, prospective study will enrol 30 patients to monitor safety and probable benefit over 24 months, with expected revenue of US$1.7 million from treatments under the PAS. This staged rollout reflects the cautious approach typical of HDE approvals, balancing early access with data collection.
Clinical Context and Unmet Need
dCCA arises in the distal common bile duct and is often diagnosed late, limiting surgical options for more than half of patients. Existing treatments focus on biliary stenting and systemic therapies, but disease progression frequently leads to complications that disrupt treatment and degrade quality of life. The OncoSil™ device delivers targeted radiation directly into the tumour via endoscopic ultrasound-guided injection of Phosphorous-32 microparticles, potentially improving local tumour control with fewer side effects than external beam radiotherapy.
Dr Juan Valle, Chief Medical Officer at the Cholangiocarcinoma Foundation, highlighted the significance of this approval, noting it provides a new therapeutic option for a rare cancer with few treatments. OncoSil’s CEO Nigel Lange emphasised the milestone as transformational for the company and a critical step toward addressing unmet clinical needs in the US.
Next Steps in US Market Penetration
OncoSil Medical will now focus on establishing priority treatment centres, engaging key opinion leaders, and advancing reimbursement pathways, including an application for Transitional Pass-Through Payment Status in early FY26. The company also plans to ramp up clinician education and marketing efforts to support patient identification and treatment adoption.
This FDA approval complements OncoSil’s recent regulatory progress, including approvals in Europe, the UK, Australia, and Saudi Arabia, and follows a 53% increase in unit sales and regulatory advancements earlier this year. The US launch will be a critical test of the company’s ability to translate regulatory success into commercial momentum in the world’s largest healthcare market.
Bottom Line?
OncoSil’s FDA HDE approval unlocks a new US market with high unmet need, but early commercial scale will hinge on successful post-approval study outcomes and reimbursement progress.
Questions in the middle?
- How quickly will OncoSil expand beyond the initial five treatment centres under the FDA’s post-approval study?
- What reimbursement hurdles remain for OncoSil to secure broader US market access beyond the HDE pathway?
- Will clinical adoption accelerate if post-approval study data confirm safety and probable benefit in real-world settings?